Major Shareholder Converts Preferred Stock, Backs Obsidian Merger with 26.5% Stake

summarizeSummary

Emerald Bioventures, holding 26.5% of Galera Therapeutics' common stock, converted a significant portion of its preferred shares and formally committed to supporting the pending merger with Obsidian Therapeutics.

check_boxKey Events · Ownership and Investor Activity · GRTX

• Major Stock Conversion

  Emerald Bioventures converted 37,158,187 shares of Series B Preferred Stock into common stock on April 7, 2026, following a partial mandatory conversion initiated by the Issuer.

• Significant Ownership Stake

  Following the conversion, Emerald Bioventures now beneficially owns 40,216,160 shares of common stock, representing 26.5% of the outstanding shares.

• Merger Support Agreement

  Emerald Bioventures formally committed to voting its 26.5% stake in favor of the pending merger with Obsidian Therapeutics, as part of a broader support agreement with other major shareholders, which was announced on April 14, 2026.

auto_awesomeAnalysis · GRTX · Life Sciences

This Schedule 13D filing reveals Emerald Bioventures, a significant investor, has converted over 37 million shares of Series B Preferred Stock into common stock, increasing its common stock ownership to 26.5%. This conversion, while dilutive, is a step in the company's capital structure adjustments. Crucially, Emerald Bioventures has also entered into a Stockholder Support Agreement, pledging its 26.5% stake to vote in favor of the definitive merger agreement with Obsidian Therapeutics, announced on April 14, 2026. This strong commitment from a major shareholder significantly de-risks the merger's approval, which is vital for Galera Therapeutics given its previously disclosed "going concern" warning.